Divergent Trades: Intuitive Surgical's Record Quarter Fails to Unite Investors

Intuitive Surgical shares dropped 25% despite a Q1 earnings beat, as institutional investors diverge, FDA recalls and competition loom, while Japan's 2026 reimbursement expansion offers a potential catalyst.

The market for Intuitive Surgical shares is telling two very different stories. While some institutional investors are piling in, others are fleeing en masse. Sands Capital Management added 2.7% to its stake in the fourth quarter, lifting its position to around 1.38 million shares, and Focus Partners Wealth increased its holding by nearly 42%. At the same time, Towarzystwo Funduszy Inwestycyjnych PZU SA slashed its stake by 83%, and Nicholas Investment Partners sold off more than 87% of its position. Vanguard enlarged its own holding by 11.5%, and Sargent Investment Group opened a fresh position of roughly 2,500 shares. Overall, 83.6% of the float remains in professional hands.

The conflicting behavior reflects a stock that has slid roughly 25% since the start of the year despite a standout first quarter. Revenue climbed 23% to $2.77 billion, while earnings per share of $2.50 easily beat the analyst consensus of $2.08. The company installed 431 new da Vinci systems, and recurring revenue now accounts for the bulk of its business. Yet the shares currently trade around EUR 358-360, more than 15% below their 200-day moving average and a long way from the January peak of EUR 516.50.

Analysts remain broadly positive, though their price targets vary sharply. Of 31 brokers polled, 22 rate the stock a buy, producing an average rating of 1.71 on a five-point scale. Goldman Sachs trimmed its target to $558 while keeping a buy rating, and Citi upgraded the stock to buy with a $590 target. Deutsche Bank stands alone as a seller, setting its target at $366. The mean analyst price target stands at approximately $571.

The fundamental strength is being weighed down by several clouds on the horizon. The US Food and Drug Administration issued a warning for certain surgical staplers, prompting Intuitive to recall specific models. On the competitive front, Chinese manufacturers of surgical robots are rapidly gaining ground, and OpenAI's recent move into robotics has stoked fears of a new rival entering the medical field. Insider sentiment has also turned cautious: more than 7,000 shares were sold by insiders over the past 90 days.

A potential catalyst lies in Japan, where the government will expand reimbursement for robotic-assisted procedures in June 2026. Seven new procedures will be covered. Japan had been a laggard within the company's growth story, but the new policy is expected to boost procedure volumes directly. That shift could help restore momentum in a market that has been slower to adopt the da Vinci system.

The technical picture offers little comfort. The stock's 36% volatility keeps traders on edge, and the Relative Strength Index sits at a neutral 44, providing no clear directional signal. The company is due to report second-quarter results in July, with analysts forecasting revenue of $2.82 billion. Any miss on that number could accelerate the decline. For now, Intuitive Surgical must demonstrate that its growth engine remains intact even as the stock price tells a more cautious tale.